Neil Bodick - Flexion Therapeutics Insider

Flexion Therapeutics Inc -- USA Stock  

USD 23.19  1.39  5.66%

Chief Medical Officer & Co-Founder

Dr. Neil Bodick, M.D., Ph.D. serves as Chief Scientific Officer of the Company. He was Chief Medical Officer of Flexion Therapeutics, Inc. Previously, Dr. Bodick was at Eli Lilly and Company, where he founded Chorus and served as Chief Medical Officer and Chief Operating Officer. Prior to that, Dr. Bodick was responsible for earlyphase clinical investigation at Lilly Research Laboratories. He also was Assistant Professor in the School of Medicine at the University of Pennsylvania, where his research centered on the development of computerbased systems to support imageintensive diagnosis. Dr. Bodick holds 13 patents in the areas of neuroscience and computer science and is the recipient of the Biomedical Research Service Award and the New Investigator Research Award from the National Institutes of Health.
Age: 69  Founder Since 2017      

Neil Bodick Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (24.57) % which means that it has lost $24.57 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (70.63) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 160.5 M in liabilities with Debt to Equity (D/E) ratio of 92.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Flexion Therapeutics Inc has Current Ratio of 12.67 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. The company was founded in 2007 and is headquartered in Burlington, Massachusetts. Flexion Therapeutics operates under Drugs - Generic classification in USA and traded on NASDAQ General Markets exchange. It employs 1 people.Flexion Therapeutics Inc (FLXN) is traded on NASDAQ General Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 139 people. Flexion Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Flexion Therapeutics Inc to your portfolio

Top Management

Flexion Therapeutics Inc Leadership Team
Sandesh Mahatme, Director
Scott Canute, Director, MBA
Mark Levine, President
Dan Thornton, President, MBA
John Magee, President, MBA
Neil Bodick, Founder
Mark Fraga, President
Michael Clayman, CEO
Ann Merrifield, Director
Alan Milinazzo, Director
Jon Mahlowitz, VP
Frederick Driscoll, CFO
Heath Lukatch, Director
Patrick Mahaffy, Chairman
Samuel Colella, Director, MBA
Yamo Deniz, Executive, Ph.D
Mark Stejbach, Director, MBA
Scott Kelley, President

Stock Performance

Flexion Therapeutics Performance Indicators